Treatment of Shingles Without a Rash

First-Line Treatment Options

The American College of Physicians and other guideline societies recommend oral antiviral therapy with acyclovir, valacyclovir, or famciclovir as soon as possible after diagnosis to reduce viral replication and prevent complications in patients with shingles without a rash 1
Acyclovir 800 mg orally 5 times daily for 7-10 days is a recommended treatment option for patients with shingles without a rash, with a strength of evidence based on guidelines from the Centers for Disease Control and Prevention 3, 1
Valacyclovir 1000 mg orally 3 times daily for 7 days and famciclovir 500 mg orally 3 times daily for 7 days are alternative treatment options, offering better bioavailability and less frequent dosing compared to acyclovir, which can improve adherence in patients with shingles without a rash 2

For immunocompromised patients with severe VZV infections, high-dose IV acyclovir is the treatment of choice, and immunosuppressive therapy should be temporarily discontinued, with treatment continuing for a minimum of 7-10 days, as recommended by the Infectious Diseases Society of America 2, 4, 5
Antiviral therapy should be initiated even in the absence of rash when zoster sine herpete is suspected in elderly patients, who are at higher risk for complications, including postherpetic neuralgia, according to the American Geriatrics Society 1

Patients with shingles without a rash should be monitored for complete healing and resolution of pain, with close follow-up for development of any complications, especially those who are immunocompromised, as recommended by the Centers for Disease Control and Prevention 1, 4

Topical antiviral therapy is substantially less effective than systemic therapy and is not recommended for patients with shingles without a rash, while antiviral medications do not eradicate latent virus but help control symptoms and reduce complications, according to the American Academy of Dermatology 1
For immunocompromised patients with disseminated disease, intravenous acyclovir is recommended, with a strength of evidence based on guidelines from the Infectious Diseases Society of America 2